It concerns a total of > 45 new contracts, ranging in value from 20,000 € to 1.94 M €. At location VUmc of Amsterdam UMC there was a distribution of IAO contracts with 50% in the domain of Alzheimer's disease and dementia and 30% on multiple sclerosis and 20% on other disease indications. At the location of AMC, contracts in 2018 and 2019 were mainly on Parkinson’s disease, meningitis, stroke and other disease indications. Projects include, but are not limited to, the development of novel delivery methods of biologicals across the blood brain barrier, implementation of new PET ligands for measuring changes in synaptic density in patients, implementation of new liquid biomarkers for treatment response in cohort studies and clinical trials, and testing the first gene therapy interventions for Alzheimer’s disease. The aim for 2020 is to achieve an even more balanced distribution among the various indications. The IAO also pays attention to a good balance between preclinical, translational and clinical research.
Illustrated here is the relative distribution of Industry Alliance Office contracts across disease indications and the relative contribution of preclinical, translational and clinical research contracts, at Amsterdam UMC (location VUmc) over the last six years.
Meet the Business Developers from the Industry Alliance Office (IAO) of Amsterdam Neuroscience: